Mark Thursz is professor of hepatology at Imperial College and consultant in hepatology at St Mary's Hospital, London. His clinical interests are in viral hepatitis, alcoholic liver disease and fatty liver disease. He is currently interested in developing programmes for treatment of chronic hepatitis B infection in resource poor settings to reduce the risk of hepatocellular carcinoma.
Professor Thursz' research interests are focussed on the natural history of viral hepatitis and fatty liver disease and the factors which determine chronic infection and progressive liver disease. He has a special interest in the genetic determinants of disease outcomes using genetic association and genome wide scanning to identify causative variants.
Professor Thursz is chief investigator on two multi-centre trials: The warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C) trial and the steroids or pentoxifylline for alcoholic hepatitis (STOPAH) trial.
Professor Thursz is a former secretary of the British Association for Study of the Liver (BASL) and is currently vice-secretary of the European Association for Study of the Liver. In this role he has special responsibility for EU policy and advocacy in Brussels.
Lemoine M, 2023, Clinical characteristics and outcomes of patients with cirrhosis and hepatocellular carcinoma in The Gambia, west Africa: a prospective cohort study, The Lancet Global Health, Vol:11, ISSN:2214-109X, Pages:E1383-E1392
et al., 2023, Dysregulated anti-oxidant signalling and compromised mitochondrial integrity negatively influence regulatory T cell function and viability in liver disease., Ebiomedicine, Vol:95
et al., 2023, Alcohol-Associated Liver Disease: Integrated Management With Alcohol Use Disorder., Clin Gastroenterol Hepatol, Vol:21, Pages:2124-2134
et al., 2023, Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2., J Gen Virol, Vol:104
et al., 2023, Rapid Point-of-Care Test for Hepatitis B Core-Related Antigen to Diagnose High Viral Load in Resource-Limited Settings., Clin Gastroenterol Hepatol, Vol:21, Pages:1943-1946.e2